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Abstract 44 
Dialysis adequacy is traditionally based on urea clearance, adjusted for 45 
total body volume (Kt/Vurea), and clinical guidelines recommend a Kt/Vurea 46 
target for peritoneal dialysis (PD). We wished to determine whether adjusting 47 
dialysis dose by resting (REE) and total energy expenditure (TEE), would alter 48 
the delivered dialysis dose. 49 
 We determined REE and TEE by equations based on doubly labelled 50 
isotopic water studies, and adjusted Kturea for REE and TEE.  51 
We studied 148 PD patients, 97 male (65.5%), 54 diabetic (36.5%), mean 52 
age 60.6±17.6 years. The mean REE was 1534±241 kcal/day and TEE 1974±414 53 
kcal/day. Adjusting Kt for REE showed a reduced delivered dialysis dose (ml 54 
/kcal/day) for women vs men (5.5±0.4 vs 6.2±0.6), age < 65 vs > 65 years 55 
(5.6±0.56 vs 6.4±0.5), weight < 65 kg vs >80 kg (5.8±0.6 vs 6.1±0.5), low co-56 
morbidity vs high co-morbidity (6.2±0.6 vs 5.9±0.6), all p<0.01. Adjusting for TEE 57 
showed reduced dosing for those employed vs no employment (4.3±0.7 vs 58 
4.8±0.8), low frailty vs high frailty score (4.5±08 vs 5.0±0.7), both p<0.01.   59 
Adjusting the dialysis target dose for REE shows that for the same Kt 60 
urea, women, younger, smaller and less co-morbid patients would all receive less 61 
dialysis, and adjusting for TEE additionally shows that those employed and 62 
physically fitter would receive less dialysis.  The current paradigm for a single 63 
target Kt/Vurea for all PD patients does not take into account energy 64 
expenditure and metabolic rate, and may lead to lowered dialysis delivery for 65 
the younger more active female patient.  66 
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 67 
Introduction 68 
 More than 2 million patients with end stage kidney disease are currently 69 
treated by dialysis worldwide, with around 300,000 treated by peritoneal 70 
dialysis. As with for haemodialysis, there are clinical guidelines recommending 71 
that patients receive a minimal amount of dialysis based on urea clearance [1]. 72 
These urea based clearance targets are derived from observational studies [2]. 73 
However prospective studies comparing different peritoneal dialysis regimes 74 
designed to achieve different urea clearance targets consistently failed to 75 
demonstrate any advantage for greater urea clearance, in terms of patient 76 
morbidity or mortality [3-5]. Indeed peritoneal dialysis technique and patient 77 
survival have been linked to preservation of residual renal function [6], rather 78 
than peritoneal dialysis urea clearance [7]. 79 
 The amount of urea clearance, Kt/Vurea, for dialysis patients are 80 
currently based on volume of distribution of urea, total body water (TBW) 81 
derived from anthropomorphic measurements [8]. However total body water 82 
varies with body composition, as some tissues, such as muscle contain more 83 
water than fat [9], and also varies between racial groups [10], and patients with 84 
diabetes and other co-morbidities [11]. As such for the same Kt/Vurea, the 85 
delivered urea clearance has been suggested to differ between patients [12]. 86 
 Rather than dosing the amount of dialysis required on urea clearance 87 
based on volume of distribution, an alternative approach based upon metabolic 88 
activity has been proposed [13]. Urea is generated as a by-product of 89 
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intracellular nitrogen metabolism. Total body metabolic activity is a composite of 90 
resting metabolic rate and that due to physical activity. Previous studies in 91 
peritoneal dialysis patients have concentrated on measuring resting energy 92 
expenditure (REE) [14,15], but this under estimates total energy expenditure 93 
(TEE), by excluding that due to activity energy expenditure (AEE), 94 
 We recently validated an assessment of TEE, and REE in dialysis patients 95 
using a patient self-reported questionnaire and double isotopic labelled water 96 
[16]. To establish whether there is a difference in the amount of dialysis 97 
delivered for a fixed Kt/Vurea target, we calculated urea clearance adjusted 98 
for energy expenditure, to determine whether some groups of patients would be 99 
disadvantaged under current clinical guideline recommendations. 100 
 101 
Patients and methods 102 
  Adult patients with end stage kidney disease established on 103 
peritoneal dialysis were recruited from University College London partner 104 
hospitals when attending for outpatient assessments of peritoneal dialysis 105 
adequacy. Corresponding spent dialysate effluent, 24 hour urine collections and 106 
serum samples were analysed by standard methods, and weekly dialysis dose 107 
calculated as Kt/Vurea. Protein Nitrogen Appearance   rate was estimated using 108 
the Bergström equation, and normalised for body weight (nPNA) g/kg/day [17]. 109 
Patient demographics were obtained from computerised hospital records and 110 
comorbidity determined using a self-administered co-morbidity grading [18], and 111 
a recognised frailty score [19]. 112 
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 Total body water was calculated using the Watson equation [20]. In 113 
addition we measured total body water by bioimpedance (InBody 720, InBody, 114 
Seoul, South Korea; Body Composition Monitor (BCM), Fresenius, Bad Homberg, 115 
Germany) which was performed in a standardised manner in 118 patients [21,22]. 116 
Bioimpedance measurements made by the BCM and InBody were standardised 117 
using previously derived equations [23].Body surface area was calculated using 118 
the Gehan and George equation as recommended by the European Best Clinical 119 
Practice guidelines [24].. 120 
Physical activity data was obtained using the Recent Physical Activity 121 
Questionnaire (RPAQ) [16], which collects information about both activity and 122 
the time spent performing activities over the preceding four weeks; 123 
encompassing activities performed at home, work and during leisure time. The 124 
RPAQ has been validated against doubly labelled water technique in general 125 
population [16], and has been shown to be a reliable tool for estimation of energy 126 
expenditure in patients with chronic kidney disease [25]. Physical activity data 127 
was determined by each reported activity being assigned a Metabolic Equivalent 128 
of Task (MET) value according to the Compendium of Physical Activities [26]. 129 
The equations for calculating REE and TTE are detailed in the Appendix. 130 
UK clinical guidelines recommend a minimum weekly Kt/V of 1.7 [1]. Hence, 131 
in order to compare minimum dialysis targets using alternative scaling 132 
parameters, weekly Kt was calculated as Kt = 1.7 * V. Corresponding target 133 
values of Kt/BSA, Kt/REE and Kt/TEE were calculated by dividing daily Kt by 134 
the respective parameters. 135 
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Ethical approval was granted by the UK National Research Ethics 136 
Committee - Essex and the study was registered in UK Clinical Research 137 
Network (CRN) Portfolio number 14018. All patients provided written informed 138 
consent in keeping with the declaration of Helsinki. 139 
 140 
Statistical analysis 141 
 Statistical analysis was by students’ t test, or Mann Whitney U test, 142 
ANOVA and Kruskal Wallis , with appropriate post hoc correction, Pearson or 143 
Spearman’s test for univariate correlation (GraphPad Prism version 6.0, San 144 
Diego, USA) and step backward linear regression, of variables on univariate 145 
analysis of p<0.1, with log transformation of variables which were not normally 146 
distributed, and removal of variables which were not statistically significant 147 
unless they improved model fit, and models were checked for collinearity (SPSS 148 
version 22, University of Chicago, Illinois, USA), and Bland Altman comparison 149 
(Analyse-It version 3.0, Leeds, UK). Data are presented as mean ± standard 150 
deviation, median (inter quartile range), or mean and 95% confidence limits (CL), 151 
or as a percentage. 152 
 153 
Results 154 
We studied 148 patients, 97 male (65.5%), 54 diabetic (36.5%), mean age 155 
60.6±17.6 years, with a median duration of peritoneal dialysis 9.1 (3.5-25.2) 156 
months. The median co-morbidity score was 2 (0-3.8), and frailty score 4 (2-5). 157 
43.2% of patients were Caucasian, 27.1% African-Afro-Caribbean, 24.3% South 158 
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Asian, and 5.4% Far Asian. A minority, 20.3% of patients had some form of 159 
employment.  160 
Mean haemoglobin was 109.9±14.8 g/l, with a serum albumin 36.5±5.5 g/l 161 
and serum C reactive protein (CRP) 6 (2-16) mg/l. Mean weight of the cohort was 162 
73.6±16.7 kg, BMI 26.0±4.9 kg/m2, and BSA 1.86±0.24 m2. The majority of 163 
patients were treated by automated peritoneal dialysis cyclers (APD) 85.8% vs 164 
14.2% by continuous ambulatory peritoneal dialysis (CAPD). The median total 165 
weekly Kt/Vurea was 2.15 (1.8-2.71), with a median 24 hour urine volume of 946 166 
(450-1249) ml/day. The mean REE was 1534±241 kcal/day and TEE 1974±414 167 
kcal/day. Mean PNA was 64.5±19.7 g/day and nPNA 0.89±0.26 g/kg/day. 168 
 Male patients were heavier than female (77.0±15.6 vs 72.6±16.6 kg), and 169 
had greater REE and TEE (table 1). Patients who were employed, those with 170 
greater weight, and greater PNA had higher TEE (Table1), whereas those with 171 
greater frailty and co-morbidity, and those who were diabetic and Asian 172 
patients tended to have lower TEE.  173 
We then adjusted a weekly Kturea of 1.7 for all patients for both BSA 174 
and TBW. Bland Altman analysis showed that for both men and women the 175 
adjusted Kturea was greater for smaller patients with a relatively greater BSA 176 
to TBW, and lower for larger patients with a relatively lower BSA compared to 177 
TBW (Figure 1).  178 
In a subset of 118 (79.7%) of the study group; 75 male (63.6%), 33 179 
diabetic (28.5%), mean age 59.3±18.2 years, with a median duration of peritoneal 180 
dialysis 9.4 (3.8-25.5) months, we also measured TBW by bioimpedance. The 181 
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mean weight of this cohort was 73.1±16.6 kg with a body mass index of 26.0±4.9 182 
kg/m2, with a median co-morbidity grade of 2 (0-4) and frailty score of 4 (2-5), 183 
and did not differ from the main study group. There was no significant 184 
difference in TBW: Watson equation 40.3±6.1 vs bioimpedance 40.6±3.4 L, mean 185 
difference on Bland Altman analysis 0.72 L (Figure 2). There were positive 186 
correlations between BSA and both REE and TEE (r=0.92, p<0.001 and r =0.59, 187 
p<0.001) and also between TBW and both REE and TEE (r=0.85, p<0.001 and 188 
r=0.62, p<0.001) respectively. 189 
 We then calculated Kt values for a prescribed Kt/V of 1.7 using for  190 
both Watson and bioimpedance estimates of TBW  These values were then  191 
patients from adjusted by BSA, REE and TEE. The results are shown in Table 2 192 
and Figure 3 for different patient groups For the same prescribed dialysis dose, 193 
women, younger patients, those employed and those weighing less (Figure 3) 194 
received less dialysis than men, older patients, those not employed and heavier 195 
patients (table 2). In addition generally patients with less co-morbidity and 196 
frailty and non-Asian races also tended to receive less dialysis than those who 197 
were more co-morbid, frail and of Asian ethnicity. 198 
We used a step backward approach to develop multivariable models of 199 
adjusted Kt, including all variables with p<0.1 on univariate analysis, and then 200 
eliminating variables which were not significant or did not improve model fit to 201 
determine associations with adjusted dialysis dose. Sex was a significant 202 
predictor of Kt/BSA. Sex and age were significant predictors of Kt/REE. the 203 
predominant variables (table 3). For Kt/TEE, sex, age and employment were 204 
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common predictive factors whether Kt was derived using TBW derived by 205 
Watson and bioimpedance methods. Both high co-morbidity, and diabetes were 206 
additional predictive factors for TEE adjusted using the Watson formula for 207 
TBW (table 3).  208 
  209 
 210 
Discussion 211 
Traditionally the target dialysis for patients with end stage kidney 212 
failure has been based on urea clearance adjusted for total body water volume. 213 
However multiple prospective trials have failed to show an association between 214 
greater peritoneal dialysis urea clearance and survival [3,4,7]. Cellular 215 
metabolism, in particular protein turnover generates waste products which 216 
accumulate in patients with end stage kidney failure.  As these azotaemic toxins 217 
are generated by cellular metabolism, it has been suggested that the amount of 218 
dialysis required for patients should be based on metabolic rate, rather than 219 
urea clearance [2]. Studies to-date have concentrated on measuring resting 220 
metabolic rate [3], but this ignores physical activity, and as such potentially 221 
under estimates energy expenditure. We used equations based on patient self-222 
reported physical activity questionnaires, which have been validated using doubly 223 
labelled isotopic water [4], to estimate REE and TEE. As expected energy 224 
expenditure was associated with body weight, male sex and younger age group 225 
[27]. Patients with higher REE and TEE had greater PNA rate due to increased 226 
urinary and peritoneal urea losses However we also noted that although REE was 227 
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similar, TEE was lower with increasing frailty and co-morbidity, in particular 228 
diabetes, and those without employment compared to those patients with lower 229 
frailty and co-morbidity scores, who were not diabetic or those with 230 
employment. We also found that patients from an Asian background had lower 231 
TEE compared to Caucasoids and African-Afro-Caribbean patients. This is in 232 
keeping with previous observations of lower energy expenditure, particularly 233 
with South Asians, and this has been suggested to be due to differences in 234 
terms of body composition, related to brown fat tissue stores [28].  235 
We then compared the delivered dialysis dose for the minimum weekly 236 
KtVurea target as recommended by clinical practice guidelines [1], using Kt 237 
calculated by both the Watson formula [20], and also total body water measured 238 
by bioimpedance [29]. We found no significant difference between total body 239 
water by either method, although previous reports from haemodialysis patients 240 
have reported differences [9]. However the major differences between total 241 
body water derived by the Watson formula and bioimpedance were with obese 242 
patients with a body mass index of > 35, and in our study group < 2% had a body 243 
mass index of this level.  We adjusted the delivered dialysis dose by both BSA, 244 
which is relatively greater for patients with lower total body water, and 245 
relatively lower for those with greater total body water and also for both REE 246 
and TEE. Adjusting Kt for BSA, which has been advocated for haemodialysis 247 
patients, we found that this resulted in a lower dose being delivered to women 248 
and those with a high protein nitrogen appearance rate and lower body weight. 249 
Whereas adjusting for REE, then female patients, and those who were younger, 250 
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weighed less, and who had lower protein nitrogen appearance along with those 251 
with frailty and co-morbidity scores, and other ethnicities than Asian all 252 
received relatively less delivered dialysis. When Kt was adjusted for TEE, then 253 
women, younger patients and those weighing less, who were employed, and those 254 
with less frailty, in particular those with diabetes, all would receive less 255 
delivered dialysis dosing compared to men, heavier patients, those without 256 
employment and the more frail, co-morbid patient and those with diabetes. 257 
Previous studies targeting a dialysis dose defined by a weekly KtVurea 258 
for peritoneal dialysis patients have not shown an advantage for one target 259 
compared to another [3,4]. Our study shows that achieving the same urea 260 
clearance does not equate to the same delivered dose of dialysis, and as such 261 
potentially adds explanation as to why prospective studies have failed to show a 262 
significant benefit for one KtVurea target for all patients. Although we 263 
accepted that using Kt/Vurea for dialysis dosing has some limitations [31], more 264 
recent observational studies have suggested an advantage for adjusting Kt for 265 
BSA [30]. However we found that although adjusting for BSA detected a 266 
difference between sexes and body weight, those who had higher nitrogen 267 
appearance rates. Whereas in particular adjusting for TEE showed that in 268 
addition, younger fitter patients received relatively less dialysis dose delivered 269 
compared to older, more frail, co-morbid and diabetic patients. As such we 270 
suggest that a single Kt/Vurea target dose us not applicable to all patients, and 271 
the dose of dialysis should be increased for those who are more physically 272 
active with greater TEE. 273 
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 391 
 392 
Figure 1: Relationship between body surface area (BSA) and Watson total body 393 
water for man and women. 394 
. 395 
Figure 2: Bland Altman analysis of total body water (TBW) measured by 396 
bioimpedance or calculated by Watson equation. Mean difference 0.72 L (95% 397 
limits of agreement -9.2 to +10.7 L). 398 
 399 
Figure 3:  Adjusted daily urea clearance according to body weight. Fixed weekly 400 
Kt of 1.7urea adjusted for body surface area (BSA) and resting energy (REE) 401 
and total energy (TEE) expenditure using Watson total body water (W) or 402 
bioimpedance measured total body water (BIA).* p <0.05, and **p<0.01  vs weight 403 
< 64 kg after Bonferroni correction. 404 
 405 
 406 
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Table 1. Estimates of daily resting energy expenditure (REE) and total energy 407 
expenditure (TEE) in patients according to age, co-morbidity, frailty and 408 
ethnicity groupings. Daily protein nitrogen appearance (PNA) g/day. Results 409 
expressed as mean ±standard deviation, or median (interquartile range). *p<0.05, 410 
** p<0.01 comparing groups, adjusted for multiple comparisons (Bonferroni 411 
method).  412 
 413 
variable REE kcal/day TEE kcal/day 
male 1597±217 2029±423 
female 1412±240** 1868±377* 
Age < 65 years 1646±209 2173±392 
Age > 65 years 1408±211** 1750±314** 
Non-diabetic 1522±233 2021±435 
diabetic 1556±254 1893±366* 
employed 1577±237 2305±511 
not employed 1523±242 1890±340** 
Low comorbidity 1532±245 2012±441 
High comorbidity 1539±231 1862±300 
Low frailty score 1533±227 2049±453 
High frailty score 1535±256 1894±353* 
Weight < 64 kg 1305±151 1706±306 
Weight 64-80 kg 1514±142** 1973±414** 
Weight > 80 kg 1775±159** 2233±339** 
PNA < 60 g/day 1450±214 1826±317 
PNA > 60 g/day 1622±229** 2133±438** 
Non Asian 1561±225 2060±462 
Asian 1522±243 1866±359* 
 414 
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 Table 2. Comparison for a fixed total weekly Kt/V of 1.7 (urea clearance 431 
L/m2/day, or ml urea clearance/kcal/day) adjusted for body surface area (BSA), 432 
resting energy expenditure (REE), total energy expenditure (TEE) for peritoneal 433 
dialysis patients comparing sexes, age (years), diabetic, employment status, and 434 
co-morbidity, weight and ethnicity. Diabetic (DM), High (H) and Low (L) frailty, 435 
co-morbidity (Comorb), protein nitrogen appearance (PNA) employed (employ +), 436 
not employed (employ -), ethnicity (Asian vs other races). *p<0.05 **p<0.01 after 437 
Bonferroni  post hoc correction for multiple testing.  438 
  439 
variable Kt/BSA Kt/REEW Kt/TEEW Kt/REEBIA Kt/TEEBIA 
Male 5.13±.0.36 6.15±9.61 4.96±0.71 6.23±0.62 4.93±0.70 
Female 4.42±0.40** 5.50±0.41** 4.23±0.65** 5.64±0.64** 4.27±0.71** 
Age < 65  4.83±0.46 5.58±0.55 4.29±0.53 5.93±0.73 4.52±0.81 
Age > 65  4.95±0.42 6.38±0.49** 5.18±0.61** 6.12±0.62 4.93±0.65** 
DM yes 4.96±0.45 6.03±0.58 5.00±0.69** 5.92±0.65 4.93±0.69* 
DM no 4.84±0.46 5.90±0.66 4.53±0.82 6.06±0.71 4.57±0.78 
H frailty 4.91±0.47 6.06±0.66 4.96±0.75 6.01±0.61 4.90±0.71 
L frailty 4.86±0.43 5.85±0.60* 4.46±0.78** 6.01±0.75 4.54±0.78** 
HComorb 4.99±0.43 6.19±0.63 5.14±0.66 5.91±0.63 4.90±0.63 
LComorb 4.85±0.45 5.87±0.62** 4.55±0.80** 6.05±0.71 4.62±0.81 
Employ - 4.89±0.43 5.99±0.61 4.87±0.72 5.96±0.73 4.81±0.75 
Employ + 4.89±0.54 5.82±0.71 4.07±0.82** 6.19±0.51 4.31±0.72** 
H PNA 4.79±0.40 5.91±0.62 4.75±0.78 5.77±0.70 4.56±0.70 
L PNA 4.95±0.48* 5.98±0.68 4.62±0.87 6.23±0.59* 4.81±0.81 
Asian 4.87±0.46 5.97±0.65 4.67±0.85 6.10±0.65 4.71±0.76 
Other  4.87±0.42 5.90±0.60 4.79±0.69 5.79±0.76* 4.64±0.80 
 440 
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Table 3. Multivariable step backward models for weekly Kt  adjusted for Body 458 
surface area (BSA), resting energy expenditure (REE), and total energy 459 
expenditure (TEE), using both total body water calculated by Watson equation 460 
(W) and measured by bioimpedance (BIA). Unstandardised β (β), standard error 461 
(StE), standardised β (Standard β), 95% Confidence limits (95% CL). Protein 462 
nitrogen accumulation rate (PNA). 463 
Adjusted for BSA model r20.60, adjusted 0.59, model adjusted for REEW r20.60, 464 
adjusted 0.59, model adjusted for REEBIA r20.42, adjusted 0.37, model adjusted 465 
for TEEW r20.42, adjusted 0.3, and adjusted for TEEBIA r20.35, adjusted 0.33 . 466 
Sex (female vs male), age years, high co-morbidity (H).  467 
 468 
 469 
 β StE β Standard β t 95% CL p 
Kturea/BSA       
sex (M) 0.70 0.05 0.77 13.5 0.6-0.87 <0.001 
Kturea/REEW       
sex (M) 0.58 0.08 0.44 7.5 0.43-0.74 <0.001 
age 0.02 0.01 0.54 9.3 0.2-0.25 <0.001 
Kturea/REEBIA        
PNA 0.01 0.01 0.37 4.4 0.01-0.02 <0.001 
sex (M) 0.39 0.12 0.28 3.2 0.15-0.63 0.002 
age 0.01 0.01 0.19 2.3 0.01-0.01  0.025 
Kturea/TEEW        
sex (M) 0.59 0.10 0.35 6.1 0.40-0.79 <0.001 
age 0.02 0.01 0.44 7.5 0.02-0.013 <0.001 
no employment 0.52 0.11 0.26 4.5 0.29-0.74 <0.001 
comorbidity H 0.30 0.11 0.16 2.7 0.01-0.52 0.009 
diabetic 0.21 0.10 0.12 2.0 0.01-0.41 0.045 
 Kturea/TEEBIA       
sex (M) 0.51 0.13 0.33 3.8 0.25-0.77 <0.001 
age 0.01 0.01 0.32 7.5 0.01-0.02 <0.001 
no employment 0.44 0.15 0.24 3.0 0.15-0.74 0.004 
 470 
 471 
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Appendix 482 
 483 
Resting Energy Expenditure (REE) was estimated from a newer novel predictive 484 
equation which was derived and validated in a cohort of HD patients [18].  485 
 486 
REE = -2.497 * Age(years) * Factorage + 0.011 * Height2.023(cm) + 83.573 * 487 
Weight0.6291(kg) + 68.171 * Factorsex 488 
 489 
where Factor age is 0 if age <65 and 1 if ≥65 and Factor sex is 0 if female and 1 490 
if male 491 
 492 
Physical activity data - Each reported activity was assigned a Metabolic 493 
Equivalent of Task (MET) value as per the Compendium of Physical Activities 494 
[19]. Sleep time per day was assumed to be 8 hours and any unreported time 495 
during the day was assumed as the time performing light activities at home. A 496 
Mean daily MET value was calculated. 497 
 498 
Total Energy Expenditure (TEE) was estimated from the following equation. 499 
  TEE = REE * Mean Daily MET 500 
.   501 
 502 
 503 
 504 
 505 
 506 
 507 
 508 
 509 
 510 
 511 
 512 
 513 
